Hepatitis B Surface Antigen
Hepatitis B Virus Infection
Explore 22 assets in Hepatitis B Virus Infection →Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Central Hospital, Nancy, France
Modality
vaccine
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05028322CT.gov Evaluation of Intradermal Hepatitis B Vaccine After IMIQUIMOD's Application, in Cirrhotics Who Did Not Respond to the Usual Vaccine Regimen | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hepatitis B Virus Infection
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Hepatitis B Surface Antigen (this asset) | Central Hospital, Nancy, France | P2 | CCC · 53 |
| Entecavir | Sun Yat-sen University | P4 | BBB |
| Lamivudine | Fudan University | P4 | BBB |
| Tenofovir | Ruijin Hospital | P4 | BB |
| Tenofovir Bis(Isopropyloxycarbonyloxymethyl) Ester | West China Hospital | P4 | BB |
| Hepatitis B Virus Vaccine | Eunice Dube | P4 | BB |
| Hep-V Vax | University of Oxford | P4 | BB |
| Tenofovir Alafenamide | Sun Yat-sen University | P4 | BB |
| Besifovir Dipivoxil | IlDong Pharmaceutical Co Ltd | P4 | BB |
+34 more in the Hepatitis B Virus Infection cohort
Other indications for Hepatitis B Surface Antigen
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Cirrhosis Of Liver | — | P2 | CCC · 53 |
| Rectal Carcinoma | — | P2 | CCC · 51 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Hepatitis B Surface Antigen in Hepatitis B Virus Infection. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/hepatitis-b-surface-antigen-hepatitis-b-virus-infection
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →